---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-252194"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:24:26.724546+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma Q3 revenue $128.7M (+25% YoY); GAAP EPS $0.35; raises FY guidance

## Summary
- Total revenue $128.7M, up 25.3% YoY; GAAP net income $43.9M ($0.35 diluted).
- Non-GAAP net income $71.1M ($0.57 diluted); cash and equivalents $442.3M.
- FIRDAPSE net rev $79.3M (+19.7%); AGAMREE early launch $15.0M; FYCOMPA $32.1M.
- Full-year 2024 total revenue guidance raised to $475-485M.
- Q3 2023 GAAP net loss of $30.8M vs. current net income of $43.9M.

## SEC filing metadata
- accession: 0001193125-24-252194
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312524252194/0001193125-24-252194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312524252194/d882968d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-252194
- JSON: https://secwatch.observer/filing/0001193125-24-252194.json
- Plain text: https://secwatch.observer/filing/0001193125-24-252194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.